SML1928
UM-164 trifluoroacetate salt
≥98% (HPLC)
别名:
2-[[6-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-5-thiazolecarboxamide trifluoroacetate salt
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C30H31F3N8O3S · xC2HF3O2
CAS号:
分子量:
640.68 (free base basis)
分類程式碼代碼:
12352200
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
H2O: 10 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
OCCN(CC1)CCN1C2=CC(NC3=NC=C(C(NC4=CC(NC(C5=CC(C(F)(F)F)=CC=C5)=O)=CC=C4C)=O)S3)=NC(C)=N2
生化／生理作用
UM-164 is a potent dual c-Src/p38 kinase inhibitor that exhibits potent anti-TNBC activity in xenograft models. UM-164 inhibits p38 kinase and binds to an inactive c-Src conformation. UM-164 has a high therapeutic index in vivo.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Frank E Kwarcinski et al.
ACS chemical biology, 11(5), 1296-1304 (2016-02-20)
In the kinase field, there are many widely held tenets about conformation-selective inhibitors that have yet to be validated using controlled experiments. We have designed, synthesized, and characterized a series of kinase inhibitor analogues of dasatinib, an FDA-approved kinase inhibitor
Rabia A Gilani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(20), 5087-5096 (2016-05-08)
c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In the clinic, however, the limited efficacy and high toxicity of existing c-Src inhibitors have tempered the enthusiasm for targeting c-Src. We developed a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门